Results 141 to 150 of about 1,300 (156)

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology, 2020
Neal Lakdawala, Andrew Wang, Jay Edelberg   +2 more
exaly  

Reflections on community experience with Mavacamten

Progress in Cardiovascular Diseases
Eiswirth, Clement, Gilliland, Yvonne E.
openaire   +4 more sources

Effects of mavacamten on Ca2+ sensitivity of contraction as sarcomere length varied in human myocardium

British Journal of Pharmacology, 2020
Campbell Ks, Bertrand C W Tanner
exaly  

A Collaborative Approach to Mavacamten Care: A Pharmacist-Nurse Led Mavacamten Monitoring Program

Heart, Lung and Circulation
V. Warner, E. Paratz, R. Downes, A. Considine, K. Easton, S. Crute, D. Huynh, S. Harberts, L. Toner, A. Ellims, N. Sutherland, H. Patel   +11 more
openaire   +1 more source

Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers

Proceedings of the National Academy of Sciences of the United States of America, 2018
Joshua Gorham, Makenna Morck, Eric Green   +2 more
exaly  

Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug–Drug Interaction Studies in Healthy Participants

Clinical Pharmacology in Drug Development, 2023
exaly  

Mavacamten/sotalol

Reactions Weekly
openaire   +1 more source

Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM

JACC: Cardiovascular Imaging
Anjali Tiku Owens, Mark Sherrid, David Fermín   +2 more
exaly  

Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten

Heart Rhythm
John Giudicessi, Said Alsidawi, Adelaide Arruda-Olson   +2 more
exaly  

Mavacamten (▼Camzyos) for obstructive hypertrophic cardiomyopathy

Drug and Therapeutics Bulletin
openaire   +2 more sources